رجوع

Nutex Health, Inc.

جودة البيانات: 100%

NUTX

NASDAQ Healthcare Medical - Healthcare Information Services

KWD 99.49

▲ KWD 4.51 (4.75%)

القيمة السوقية: 592.40M

نطاق اليوم

KWD 93.02 KWD 100.73

نطاق 52 أسبوعًا

KWD 45.88 KWD 193.07

حجم التداول

175,497

متوسط 50 يوم / 200 يوم

KWD 122.92 / KWD 118.80

الإغلاق السابق

KWD 94.98

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (627 نظير)

المقياس	السهم	وسيط القطاع
P/E	8.4	0.3
P/B	1.8	2.9
ROE %	29.8	3.7
Net Margin %	8.1	3.8
Rev Growth 5Y %	27.5	10.0
D/E	1.1	0.2

السعر المستهدف للمحللين

Hold

KWD 205.000 +106.1%

مكرر الربحية المستقبلي

6.2

ربحية السهم المستقبلية

KWD 15.410

نمو ربحية السهم (تقدير)

+0.0%

الإيرادات المقدّرة

910 M

تقديرات الأرباح

الفترة	تقدير ربحية السهم	تقدير الإيرادات	المحللون
FY2027	KWD 17.555 KWD 16.792 – KWD 18.623	950 M	1
FY2026	KWD 15.410 KWD 14.740 – KWD 16.347	910 M	1

النقاط الرئيسية

Revenue grew 27.47% annually over 5 years — strong growth

Earnings grew 35.67% over the past year

ROE of 29.76% indicates high profitability

Generating 245.60M in free cash flow

P/E of 8.37 — trading at a low valuation

Revenue growth is accelerating — 1Y growth exceeds 5Y average by 54.89%

النمو

Revenue Growth (5Y)

27.47%

Revenue (1Y)82.36%

Earnings (1Y)35.67%

FCF Growth (3Y)N/A

الجودة

Return on Equity

29.76%

ROIC30.36%

Net Margin8.09%

Op. Margin31.49%

الأمان

Debt / Equity

1.07

Current Ratio3.41

Interest Coverage12.40

التقييم

P/E Ratio

8.37

P/B Ratio1.80

EV/EBITDA2.75

Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y)	82.36%	Revenue Growth (3Y)	88.00%
Earnings Growth (1Y)	35.67%	Earnings Growth (3Y)	N/A
Revenue Growth (5Y)	27.47%	Earnings Growth (5Y)	-14.52%
Profitability
Revenue (TTM)	875.26M	Net Income (TTM)	70.79M
ROE	29.76%	ROA	7.71%
Gross Margin	50.76%	Operating Margin	31.49%
Net Margin	8.09%	Free Cash Flow (TTM)	245.60M
ROIC	30.36%	FCF Growth (3Y)	N/A
Safety
Debt / Equity	1.07	Current Ratio	3.41
Interest Coverage	12.40	Dividend Yield	0.00%
Valuation
P/E Ratio	8.37	P/B Ratio	1.80
P/S Ratio	0.68	PEG Ratio	1.77
EV/EBITDA	2.75	Dividend Yield	0.00%
Market Cap	592.40M	Enterprise Value	758.21M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	875.26M	479.95M	247.65M	219.29M	331.53M
Net Income	70.79M	52.18M	-45.79M	-424.78M	132.59M
EPS (Diluted)	10.48	9.71	-10.39	-100.36	33.55
Gross Profit	444.28M	196.26M	34.77M	15.42M	179.28M
Operating Income	275.63M	130.62M	-31.77M	-406.60M	170.26M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Total Assets	918.53M	655.32M	398.25M	431.75M	394.65M
Total Liabilities	495.09M	453.43M	319.14M	311.42M	203.07M
Shareholders' Equity	329.45M	146.34M	61.45M	95.86M	114.65M
Total Debt	351.39M	340.30M	275.76M	267.20M	178.55M
Cash & Equivalents	185.57M	43.58M	22.00M	34.26M	36.12M
Current Assets	538.81M	292.48M	90.85M	97.97M	154.02M
Current Liabilities	157.91M	140.87M	58.31M	54.86M	37.69M

درجات الاستراتيجيات

This stock passed the criteria for 5 strategies

Score = fit strength (0–100)

Rank = position among all matches

Custom Cash Flow Compounder

#89 of 1052

Growth Price/Sales Ratio Focus (Ken Fisher)

#19 of 618

Custom Contrarian Investing (David Dreman)

#165 of 670

Growth Growth Investing (Philip Fisher)

#43 of 157

Custom Full Throttle

#26 of 146

النشاط الأخير

دخل Cash Flow Compounder

Mar 24, 2026

دخل Price/Sales Ratio Focus (Ken Fisher)

Mar 24, 2026

دخل Contrarian Investing (David Dreman)

Mar 24, 2026

دخل Growth Investing (Philip Fisher)

Mar 24, 2026

دخل Full Throttle

Mar 24, 2026